Thank you all for this subreddit.

permalink

Unfortunately NOT about ivermectin IN Germany. AFAIK there isn't a trace of interest in ivermectin there, aside from one doctor who is using it.

AN ANTI-PARASITIC AGENT AGAINST COVID-19?

#Ivermectin: Ardent Supporters and Rational Skeptics

REMAGEN - JANUARY 11TH, 2021, 5:50 PM

Especially in South American countries with high numbers of infections there has been a hype about ivermectin against COVID-19. In the United States, the FDA felt compelled to discourage the use of ivermectin veterinary drugs to prevent abuse.

For a long time, at least in Europe, it had been relatively quiet about ivermectin as a potential COVID-19 therapeutic agent. Now there's a lot of rumor after a US body presented the results of a comprehensive meta-analysis in December. The result is a fiery plea for the wider use of the anti-parasitic drug, which is believed to have highly effective antiviral and anti-inflammatory properties against SARS-CoV-2 and COVID-19.

During the feverish search for potent COVID-19 therapeutics that could also be made available quickly for treatment, Ivermectin became the focus of interest in April of last year 2020. Australian scientists had observed that the anti-parasitic drug, which is on the WHO's "Essential Medicines List", almost completely eliminated SARS-CoV-2 in a cell model within 48 hours. As a result, there was a real hype about the drug in many, especially South American countries with high numbers of infections. In the United States, the FDA felt compelled to discourage the use of ivermectin veterinary drugs to prevent abuse.

In the meantime, research into the anti-parasitic agent has gained considerable momentum. Cinicaltrials.gov currently lists (as of January 8, 2021) 46 studies. 14 of them are "completed". Even so, ivermectin has not been the focus of attention in either the US or Europe in recent months when it comes to repurposed, already approved therapeutics for COVID-19.

Comprehensive meta-analysis presented

The "Front Line COVID-19 Critical Care Alliance" ( FLCCC ), which was founded in March 2020 and is based in Madison in the US state of Wisconsin, intends to change this soon. The alliance of intensive care physicians aims to develop evidence-based, continuously optimized treatment protocols for COVID-19. In mid-December, she presented the results of a comprehensive meta-analysis of the available data on ivermectin against COVID-19. In addition to in-vitro and animal studies, numerous controlled clinical studies (see table on page 3) as well as real-world findings were evaluated. Twelve of the 24 reviewed studies with almost 4, 000 patients have already been published in peer-reviewed journals, the rest on pre-print servers.

Conclusions from the studies

The FLCCC Recommendation draws the conclusion, from the entirety of the clinical data, that ivermectin can significantly reduce viral load. It is also said to curb the transmission and development of COVID-19 in infected people and to accelerate recovery and prevent deterioration in patients with mild to moderate disease when administered early after the onset of symptoms. In the case of seriously ill patients, it should help avoid hospitalization and reduce mortality in critically ill patients with COVID-19 and in regions with high infection rates also reduce case mortality. The safety profile is also considered to be advantageous and extensive application experience over almost 40 years is available. Load, but not least, ivermectin is inexpensive and therefore a realistic option for poorer countries that is available everywhere. AAs a pre-print published systematic review of eight randomized controlled trials by Australian researchers came to similar conclusions, the FLCCC experts add.

"Nature experiments" in South America

In addition to the study data, the alliance refers to the findings from several large "nature experiments" in South American countries. In May, various regional health ministries and government agencies in Peru, Brazil and Paraguay started " Ivermectin distribution campaigns " to their people. According to this, there are supposed to have been strong declines in the number of cases compared to regions without such campaigns. In Paraguay, the Alto Parana state government officially disguised an ivermectin sales campaign launched in early September as a "deworming program" because the national health ministry opposed the use of ivermectin to treat COVID-19 in Paraguay.

Similar observations have been made outside of South America. An analysis that has just been published showed that some African countries with routine prophylactic chemotherapy have significantly lower incidences of COVID-19. The reported correlation for ivermectin was very significant both when compared between African nations and in a global context. The authors therefore suggest evaluating ivermectin for possible off-label prophylactic use in certain cases in order to bridge the time until a safe and effective vaccine becomes available.

permalink